Opioid use disorder & medication treatment — an evidence-based practice resource

59%

fewer opioid overdose deaths among people on methadone in the 12 months after a non-fatal overdose — 38% on buprenorphine

17,568 adults, Massachusetts, 2012–2014 [2]

81,000+

overdose deaths in the 12 months ending May 2020 — the highest 12-month total recorded at the time [4]

28 days

of take-home methadone now permitted for stable patients, a COVID-era flexibility made permanent in 2024 [5]

Medication is the treatment. Counselling should be offered and made available — but it cannot be a condition of getting the medication.

The core clinical stance of SAMHSA TIP 63 [1]

The intervention

Medication for opioid use disorder, at three levels

Buprenorphine, methadone and extended-release naltrexone are the first-line treatment for opioid use disorder. What that means in practice is different work at each level — and the levels only produce outcomes together. [1]

Micro

The individual and family

Components

Assessment and a DSM-5 diagnosis of moderate-to-severe opioid use disorder
Induction on buprenorphine, methadone or extended-release naltrexone, chosen with the client
Counselling and psychosocial support offered — and offered, not required
Overdose education and naloxone in the client's hands
Care for what sits underneath: trauma, pain, mental health, housing

Impact

Overdose mortality drops sharply once someone is actually on medication
Withdrawal and craving stop setting the agenda for the day, which is what makes work, parenting and housing possible
Self-determination is preserved: the client picks the medication and the pace

[1]

Mezzo

Organizations and communities

Components

Prescribers, pharmacies, opioid treatment programs and social service agencies operating as one referral network
Warm handoffs at the moments people fall out of care — the emergency department, the jail door, the hospital discharge
Low-barrier and telehealth initiation so a first appointment is not a two-week wait
Staff training that removes the stigma clients feel the second they walk in
Recovery housing and employment supports that do not require abstinence from prescribed medication

Impact

Retention improves when the medication and the practical supports sit in the same network
Fewer clients are lost in the gaps between agencies, which is where most relapse happens
Organizations stop unintentionally penalizing the treatment they refer people to

[1]

Macro

Policy, funding and systems

Components

Federal rules on who may prescribe, how far a patient must travel, and how many doses they may take home
Insurance and Medicaid coverage of all three medications without prior authorization hurdles
Workforce and reimbursement policy that makes low-barrier prescribing survivable for a clinic
Data collection that shows who is and is not being reached

Impact

The 2024 final rule made pandemic flexibilities permanent: take-home methadone up to 28 days, telehealth initiation, and no more one-year-history admission rule
Where those rules loosen, access widens for rural clients and for anyone without a car or a flexible job
Coverage and rule design determine who gets treatment far more than individual motivation does

[5]

Applicability

It travels well. Access does not.

The pharmacology works the same way across populations. The delivery is where equity is won or lost, and the evidence on that is uncomfortable.

National outpatient data from 2004–2015 found buprenorphine treatment visits concentrated among white patients and among visits paid out of pocket or by private insurance. [3] A treatment that is highly effective and unevenly delivered produces unequal outcomes even when the clinical evidence is identical for everyone.

So applicability has to be judged on delivery, not just efficacy:

Methadone is the more regulated option and historically the one concentrated in clinics serving Black and low-income communities, with daily in-person dosing that collides with hourly work and caregiving.
Buprenorphine is office-based, which makes it easier to reach — for those who have a prescriber, insurance and a way to get there.
Rural clients gain the most from telehealth initiation and take-home dosing, both now permanent. [5]
Language, immigration fear and prior treatment experiences shape whether someone walks in at all — which is why the NASW cultural competence standard is a practice requirement, not a sentiment. [6]

Judging fit for a specific community

Which of the three medications is actually reachable here — today, by bus, with this insurance?
Does the dosing schedule survive this client's job and caregiving?
Will the local providers treat this client with respect?
Do our own housing and employment partners penalize prescribed medication?
Who in this community is missing from the treatment rolls, and why?

Question four is the one agencies most often get wrong about themselves.

A major life event

How a pandemic becomes a substance use disorder

Not in one step. A major life event does not create a disorder on its own — it removes the things that were holding a person steady, and then supplies a reason to cope. COVID-19 did both at scale, and the overdose curve answered within months. [4]

IsolationSupport, routine and supervision all thin out at once
LossJob loss, bereavement and financial shock arrive together
Care disruptedAppointments, groups and prescriptions become hard to reach
Use as copingSubstance use does the work that support used to do
Alone when it mattersUsing alone means nobody is there to respond

What the numbers did

More than 81,000 people died of a drug overdose in the 12 months ending May 2020 — the highest 12-month total recorded at that point. Synthetic opioid deaths rose 38.4% against the year before. CDC attributed the acceleration in part to pandemic disruption for people with substance use disorder. [4]

The policy response is the useful part of this story: the emergency loosened rules that had been defended as safety requirements for decades, access widened, and in 2024 those flexibilities were made permanent rather than reversed. [5]

For the practitioner

Professional and personal implications

Professional

Competence is a standard, not a preference. NASW requires ongoing supervision, consultation and continuing education for this population. [6]
Self-determination means the client picks. Pushing a preferred medication, or treating abstinence as the only valid goal, is an ethics problem and not just a style difference.
Medication is not a moral question. A worker who quietly regards buprenorphine as "still using" will transmit that to clients, and it will cost some of them their treatment.
Advocacy is part of the job description. Much of what limits a client's access is rule design, not clinical need. [5]
Confidentiality here is stricter than usual — substance use records carry federal protections beyond ordinary practice.
Workload management is an ethical standard, because a caseload that makes follow-up impossible is a clinical risk. [6]

Personal

You will lose clients. This field has a mortality rate, and grief that has nowhere to go turns into either numbness or burnout.
Relapse is part of the condition, not a verdict on your competence — and believing that on a hard week takes practice.
Your own history matters. Lived experience is a real professional asset and it also needs supervision; so does having none.
Secondary traumatic stress is an occupational exposure. Treat supervision as maintenance, not as evidence of a problem.
Boundaries protect the client too. The worker who cannot say no eventually becomes unavailable to everyone.
Sustainability is an ethical matter, not a personality trait: the clients need you still practising in five years. [6]

References

Sources

Each entry names the specific claim it carries, so any figure on this page can be traced to the document it came from.

Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) 63. SAMHSA Publication No. PEP21-02-01-002, 2021

Clinical components of MOUD; buprenorphine, methadone and naltrexone as first-line treatment; counselling may be offered but must not be a condition of receiving medication.

https://library.samhsa.gov/product/tip-63-medications-opioid-use-disorder/pep21-02-01-002
National Institutes of Health. Methadone and buprenorphine reduce risk of death after opioid overdose. News release, 19 June 2018, reporting Larochelle et al. in Annals of Internal Medicine; 17,568 adults in Massachusetts, 2012–2014

Opioid overdose deaths fell 59% with methadone and 38% with buprenorphine over 12 months of follow-up after a non-fatal overdose.

https://www.nih.gov/news-events/news-releases/methadone-buprenorphine-reduce-risk-death-after-opioid-overdose
Lagisetty, P. A., Ross, R., Bohnert, A., Clay, M., & Maust, D. T.. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry, 2019. doi:10.1001/jamapsychiatry.2019.0876

National outpatient data, 2004–2015: buprenorphine treatment visits were concentrated among white patients and among visits paid out of pocket or by private insurance.

https://doi.org/10.1001/jamapsychiatry.2019.0876
Centers for Disease Control and Prevention. Overdose deaths accelerating during COVID-19. Media release, 18 December 2020

More than 81,000 drug overdose deaths in the 12 months ending May 2020 — the highest 12-month total recorded at that time; synthetic opioid deaths up 38.4%. CDC attributed acceleration in part to pandemic disruption.

https://archive.cdc.gov/www_cdc_gov/media/releases/2020/p1218-overdose-deaths-covid-19.html
U.S. Department of Health and Human Services / SAMHSA. Medications for the Treatment of Opioid Use Disorder — final rule. 89 FR 7528, 2 February 2024 (RIN 0930-AA39); effective 2 April 2024, compliance 2 October 2024

Made COVID-era flexibilities permanent: take-home methadone up to 28 days for stable patients, telehealth initiation of buprenorphine (audio-only permitted) and methadone (audio-visual), and removal of the one-year opioid use history admission requirement.

https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder
National Association of Social Workers. NASW Standards for Social Work Practice with Clients with Substance Use Disorders. NASW, Washington, DC

Twelve practice standards, including Ethics and Values, Cultural Competence, Workload Management, Professional Development, and Advocacy.

https://www.socialworkers.org/Practice/NASW-Practice-Standards-Guidelines/NASW-Standards-for-Social-Work-Practice-with-Clients-with-Substance-Use-Disorders

Compiled 2026 by Access to Opportunity Corporation as an educational resource. Accuracy of a figure is only as current as its source — check the original before relying on it for clinical or policy decisions.